CSL

About CSL

CSL Limited is a global biotechnology leader with a dynamic portfolio of life-saving innovations, including vaccines, plasma therapies, and antivenoms. Founded in 1916 as the Commonwealth Serum Laboratories in Melbourne, Australia, CSL has grown into a multinational powerhouse, committed to delivering outstanding products that address some of the world’s most serious health challenges.

CSL's core mission is to save lives and protect the health of people around the world. To achieve this, the company focuses on innovation and excellence in manufacturing, research, and product development. CSL operates through two major subsidiaries: CSL Behring and Seqirus. CSL Behring is a global leader in biotherapies, dedicated to treating conditions such as immune deficiencies, hemophilia, and hereditary angioedema, as well as respiratory diseases and neurological disorders. Seqirus, one of the largest influenza vaccine providers in the world, is renowned for its innovative approaches to influenza prevention.

CSL's research and development strategy is robust, emphasizing collaboration with leading academic institutions and biotechnology companies to enhance its product pipeline and deliver on its promise of protecting public health. The company invests heavily in cutting-edge technology to improve the efficiency and effectiveness of its therapies. This includes advancements in recombinant technology, gene therapy, and cell therapy.

The company’s global reach extends to more than 60 countries, with major facilities located in Australia, the United States, Germany, and Switzerland. CSL's products are pivotal in the fight against rare and serious diseases, and its influenza vaccines play a critical role in combating annual flu epidemics worldwide.

Sustainability and corporate responsibility are key priorities for CSL. The company is dedicated to reducing its environmental impact and ensuring ethical practices across all its operations. CSL's commitment to corporate responsibility is evident in its efforts to improve patient access to its therapies, particularly in under-resourced parts of the world.

CSL continues to grow through strategic acquisitions and partnerships that complement its existing business and expand its geographic footprint. This strategy not only enhances CSL’s capacity to serve more patients but also strengthens its global leadership in the biotechnology industry.

As a company at the forefront of medical science, CSL is committed to solving some of the most complex medical challenges of our times. With a century-long history of serving the needs of the healthcare community, CSL remains dedicated to advancing its legacy of innovation and excellence in healthcare. Whether it's developing therapies that offer new hope to patients with rare diseases or providing vaccines that prevent illness on a global scale, CSL's work is a testament to its enduring commitment to enhancing the lives of people everywhere.